MREO

Mereo BioPharma Group PLC ADR

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Mereo BioPharma Group PLC ADR (MREO) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -1.2
Rev Growth YoY 0.0%
Gross Margin 73.4%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 102.8
ROE -75.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.3) B (3.3) C+ (2.5) C- (1.9) C+ (2.6)
2026-08-03 C+ (2.7) C (2.4) B (3.2) C (2.4) C- (2.0) C+ (2.5)
2026-08-02 C+ (2.7) C (2.4) B (3.2) C (2.4) C- (1.9) C+ (2.5)
2026-07-29 C+ (2.5) C+ (2.5) B- (3.0) D (1.2) D+ (1.5) C (2.2)
2025-06-30 C (2.5) C+ (2.5) B- (3.0) D (1.3) D+ (1.5) C (2.2)
Page 1 of 2